|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Validation of the Rockall scoring system for outcomes from non-variceal upper gastrointestinal bleeding in a Canadian setting显示文摘AIM: To validate the Rockall scoring system for predicting outcomes of rebleeding, and the need for a surgical procedure and death. METHODS: We used data extracted from the Registry of Upper Gastrointestinal Bleeding and Endoscopy including information of 1869 patients with non-variceal upper gastrointestinal bleeding treated in Canadian hospitals. Risk scores were calculated and used to classify patients based on outcomes. For each outcome, we used χ2 goodness-of-fit tests to assess the degree of calibration, and built receiver operating characteristic curves and calculated the area under the curve (AUC) to evaluate the discriminative ability of the scoring system. RESULTS: For rebleeding, the χ2 goodness-of-fit test indicated an acceptable fit for the model [χ2 (8) = 12.83, P = 0.12]. For surgical procedures [χ2 (8) = 5.3, P = 0.73] and death [χ2 (8) = 3.78, P = 0.88], the tests showed solid correspondence between observed proportions and predicted probabilities. The AUC was 0.59 (95% CI: 0.55-0.62) for the outcome of rebleeding and 0.60 (95% CI: 0.54-0.67) for surgical procedures, representing apoor discriminative ability of the scoring system. For the outcome of death, the AUC was 0.73 (95% CI: 0.69-0.78), indicating an acceptable discriminative ability. CONCLUSION: The Rockall scoring system provides an acceptable tool to predict death, but performs poorly for endpoints of rebleeding and surgical procedures. | Robert A Enns Yves M Gagnon Alan N Barkun David Armstrong Jamie C Gregor Richard N Fedorak RUGBE Investigators Group | 2006 | World Journal of Gastroenterology2006，12，48： | 14 |
| 2 | Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus显示文摘AIM:To assess tumour regression grade(TRG)and lymph node downstaging to help define patients who benefit from neoadjuvant chemotherapy.METHODS:Two hundred and eighteen consecutive patients with adenocarcinoma of the esophagus or gastro-esophageal junction treated with surgery alone or neoadjuvant chemotherapy and surgery between 2005and 2011 at a single institution were reviewed.Triplet neoadjuvant chemotherapy consisting of platinum,fluoropyrimidine and anthracycline was considered for operable patients(World Health Organization performance status≤2)with clinical stage T2-4 N0-1.Response to neoadjuvant chemotherapy(NAC)was assessed using TRG,as described by Mandard et al.In addition lymph node downstaging was also assessed.Lymph node downstaging was defined by cN1 at diagnosis:assessed radiologically(computed tomography,positron emission tomography,endoscopic ultrasonography),then pathologically recorded as N0 after surgery;ypN0 if NAC given prior to surgery,or pN0if surgery alone.Patients were followed up for 5 years post surgery.Recurrence was defined radiologically,with or without pathological confirmation.An association was examined between t TRG and lymph node downstaging with disease free survival(DFS)and a comprehensive range of clinicopathological characteristics.RESULTS:Two hundred and eighteen patients underwent esophageal resection during the study interval with a mean follow up of 3 years(median follow up:2.552,95%CI:2.022-3.081).There was a 1.8%(n=4)inpatient mortality rate.One hundred and thirty-six(62.4%)patients received NAC,with 74.3%(n=101)of patients demonstrating some signs of pathological tumour regression(TRG 1-4)and 5.9%(n=8)having a complete pathological response.Forty four point one percent(n=60)had downstaging of their nodal disease(cN1 to ypN0),compared to only 15.9%(n=13)that underwent surgery alone(pre-operatively overstaged:cN1 to pN0),(P<0.0001).Response to NAC was associated with significantly increased DFS(mean DFS;TRG 1-2:5.1years,95%CI:4.6-5.6 vs TRG 3-5:2.8 years,95%CI:2.2-3.3,P<0.0001).Nodal down-staging conferred a significant DFS advantage for those patients with a poor primary tumour response to NAC(median DFS;TRG 3-5 and nodal down-staging:5.533 years,95%CI:3.558-7.531 vs TRG 3-5 and no nodal down-staging:1.114 years,95%CI:0.961-1.267,P<0.0001).CONCLUSION:Response to NAC in the primary tumour and in the lymph nodes are both independently associated with improved DFS. | Fergus Noble Luke Nolan Adrian C Bateman James P Byrne Jamie J Kelly Ian S Bailey Donna M Sharland Charlotte N Rees Timothy J Iveson Tim J Underwood Andrew R Bateman | 2013 | World Journal of Gastroenterology2013，19，48： | 4 |
| 3 | An evidence-based clinical guideline for the diagnosis and treatment of lumbar disc herniation with radiculopathy显示文摘 | D. Scott Kreiner Steven W. Hwang John E. Easa Daniel K. Resnick Jamie L. Baisden Shay Bess Charles H. Cho Michael J. DePalma Paul Dougherty Robert Fernand Gary Ghiselli Amgad S. Hanna Tim Lamer Anthony J. Lisi Daniel J. Mazanec Richard J. Meagher Robert C | 2014 | The Spine Journal2014，，： | 2 |
| 4 | Sealing Pond bottoms with muddy water显示文摘 | Herman B Jamie L Robert C R | 2001 | Ecological Engineering2001，18，2： | 1 |
| 5 | Distinguishing hope and optimism:two sides of a coin,or two separate coin显示文摘 | Fred B B Jamie A C | 2004 | Joumal of Social and Clinical Psychology2004，，： | 1 |
| 6 | Mechanism of an antifungal action of selected cyclic peptides 显示文摘 | Graz M Jamie H Versluis C | 2001 | Pharmazie2001，56，： | 1 |
| 7 | Generation of Multipotential Mesendodermal Progenitors from Mouse Embryonic Stem cells via Sustained Wnt Pathway Activation显示文摘 | Manjiri MB Aina H Jamie C | | 0，，43： | 1 |
| 8 | Book Reviews--China 显示文摘 | Jami C | 2006 | The Journal of Asian Studies2006，65，2： | 1 |
| 9 | 早期乳腺癌最佳辅助化疗方案与人类表皮生长因子受体2阳性乳腺癌辅助靶向治疗选择:依据 ASCO 对 CCO临床实践指南的改编显示文摘目的研究加拿大安大略癌症治疗中心(CCO)关于早期乳腺癌最佳辅助化疗方案,包括人类表皮生长因子受体2(HER2)阳性乳腺癌辅助靶向治疗方案,并对其进行改编。方法按照美国临床肿瘤协会(ASCO)对其他组织临床实践指南改编的策略和程序,对CCO临床实践指南的严谨性与内容适用性进行回顾。结果基于对CCO临床实践指南内容的回顾,ASCO小组认为,CCO临床实践指南在整体上清晰全面,以最确切的科学证据为基础,为患者提供可接受的治疗选项。推荐关于辅助化疗方案的决定,应考虑到基线复发风险、毒性、利益可能性和宿主因素(如合并症)。对于高风险HER2阴性的身体状况良好的人群,蒽环类和紫杉烷治疗方案是标准治疗方案。4个周期的多西他赛和环磷酰胺治疗方案是可接受的非蒽环类治疗方案。对于高风险HER2阳性患者,推荐蒽环类与紫杉烷序贯疗法联合曲妥单抗或多西他赛、卡铂、曲妥单抗进行6个周期的治疗。对于低风险、非淋巴结转移、HER2阳性人群,推荐每周一次的紫杉醇和曲妥单抗连续进行12个周期的替代治疗。曲妥单抗应持续使用1年。不应采用铂复合盐对三阴性人群进行常规的辅助管理,除非出现有效的生存数据加以支持。 | Neelima Denduluri Mark R Somerfield Andrea Eisen Jamie N Holloway Arti Hurria Tari A King Gary H Lyman Ann H Partridge Melinda L Telli Maureen E Trudeau Antonio C Wolff 本刊编辑部 | 2016 | 中国全科医学2016，19，18： | 1 |
| 10 | The neglec- ted role of proaetive behavior and outcomes in newcomer socialization显示文摘 | Alan M S Jamie A G Helena C T | 2011 | Journal of Vocational Behavior2011，79，1： | 1 |
| 11 | HIF-la coordinates lymphangiogenesis during wound healing and in response to in-flammation 显示文摘 | Jamie C Zampell Yan A | 2012 | The FASEB Journal2012，26，： | 1 |
| 12 | Western influence and Chinese tradition in an eighteenth century Chinese mathematical work 显示文摘 | JAMI C | 1988 | Historial Mathematica1988，15，： | 1 |
| 13 | Relationship between self - efficacy and physical activity among patients with type 2 diabetes显示文摘 | Gareth R Bridgette C Jamie L | 2009 | Behavior Med )2009，32，： | 1 |
| 14 | Ambrisentan显示文摘 | JAMIE D C SUSAN J K | 2008 | Drugs2008，68，15： | 1 |
| 15 | Explo- ring the impact of team mental models on information uti- lization and project performance in system development 显示文摘 | Jack S C Hsu Jamie Y T Chang Gary Klein | 2011 | International Journal of Project Management2011，，29： | 1 |
| 16 | Fetal aortic valve stenosis and evolution of hypoplastic left heart syndrome:patient selection for fetal intervention显示文摘 | Kaarin M Doff B Jami C | | 0，，11： | 1 |
| 17 | Real-time human pose recognition in parts from single depth images显示文摘 | Jamie S Andrew F Mat C | 2011 | Institute of Electrical and Electronics Engineers2011，，： | 1 |
| 18 | Risk minimization and language model- ing in text retrieval显示文摘 | Zhai C Jamie Callan | 2002 | Acm Sigir Forum2002，36，2： | 1 |
| 19 | Surgery for low back pain:A review of the evidence for an American Pain Society Clinical Practice Guideline显示文摘 | Roger C Jamie B Eugene JC | | 0，，10： | 1 |
| 20 | Meta-Analysis Notes显示文摘 | | 2004 | August2004，，19： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员